Drugmakers in India may soon face stricter enforcement of quality standards. The revised Schedule M, which details manufacturing practices and quality requirements, will come into effect on January 1. The industry had expected an extension but must now comply. The enforcement includes audits and risk-based inspections to ensure compliance with the new standards.
